After the release of new FDA guidelines on risk based monitoring, News & Observer editor David Ranii spoke with our own Executive Director of Clinical Development, Mark Shapiro, to discuss what this means for the Triangle—what David refers to as the epicenter of the global CRO industry.

The current guidelines establish the framework for a more tailored approach known as risk-based monitoring (RBM). As Mark points out in the article, he believes “this is a very strong signal for the industry to move forward” with RBM and that “what the FDA is calling for is a much more customized approach.”

To read the article in its entirety, click here.

To learn more about our “technology-amplified” approach to risk-based monitoring, please click here to watch a recorded webcast and here to download our related eBook.